IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU clinical trials in 2025! 1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%. @tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO nejm.org/doi/full/10.1056/NE…

Day ONE of #PROSCA25 #GlobalForum25 in Portugal 🇵🇹 Presentation by Julien Van Damme 🇧🇪 during the Unfavourable intermediate- and high-risk PCa Session Presenting: PSA-only monitoring in BCR: Who qualifies? PSA-only biochemical recurrence represents a highly heterogeneous disease state, but clinicians can generally distinguish between two main groups: patients with slow PSA kinetics, low PSA levels, and intermediate-grade disease, who are appropriate for surveillance or local salvage approaches, and patients with rapid PSA kinetics, high PSA levels, and high-grade disease, who require prompt, intensive systemic therapy such as ARPI plus ADT for at least nine months. Additionally, monitoring PSA response helps identify which patients may safely undergo intermittent therapy, reducing treatment burden, stress, and side effects. #ProstateCancer @mdesantis234 @FontesMario @fontev1 @Silke_Gillessen @karolien_goffin @PGrivasMDPhD @bkonety @Uro_Kris @Dolmos77 @AOmlin @HenningPlage @DanieleRaggi83 @Tilki_De @BertrandTOMBAL @vandamme_jvd @roodvdb @UrsulaVogl @ZilliThomas @nataliagandur @DrRishabhOnco @mirrorsmed

Day 2 #ESMO25 Highlights: Breast Ca: 1. #DESTINYBreast11 NeoAdj TDXd 2. #DESTINYBreast05: TDXd in residual disease 3. #evERA: Giredestrant HR+ 4. #VIKTORIA1: Gedatolisib HR+ GU: 5. #KEYNOTE905: PeriOp EV + Pembro MIBC @myESMO #OncTwitter @OncoAlert @OncUpdates 1/13

🩺🎓 Training teaches the medicine, but not always the whole picture. 💡If you're starting your first attending job, you may find our article with @IvyLorena_Md on aspects of oncology that aren't taught in training helpful. 👉connection.asco.org/do/eight… #ASCOconnection @ASCO

1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest @ImmunityCP study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉authors.elsevier.com/sd/arti… #MsaouelLab

The final talk of #AtlantaGU25 👋! @virajmaster and @BasselNazha from @WinshipAtEmory join together with @DocMattCampbell from @MDAndersonNews and @shaib_walid from Northwest Georgia Oncology Centers to discuss #raretumors 🔍 in #GUoncology. Session Chair: @VikramNarayan from @WinshipAtEmory. 🌟Join us next time! Visit education.binayfoundation.or… for more upcoming CME conferences! #MedTwitter #MedX #MedEd

We’re excited to welcome all traveling speakers and attendees in ATL! See you soon @ZakhariaYousef

Expanding the application of PSMA therapy #GU25 Exciting new data on the horizon. Trials on trials on trial… and even more to come. Check out mechanisms to optimize PSMA theranostics 🔎Work needed on mechanism/resistance in PSMA neg disease 🔎We need to understanding tumor microenvironment 🔎Role of alpha emitters? Combination w/ beta emitters? @ASCO @OncoAlert @GUOncologyNow @urotoday @TargetedOnc @OncoReporte

We had a great night to focus on GU oncology with colleagues across the town @OncLive @OncLiveSOSS @WinshipAtEmory

Northwell heme/onc fellows, @DivyaReddyMD, @mneuman96g were unable to attend #WCLC2024 but I am so proud of their work and dedication to lung cancer research.

So glad to have you Jordan!

Congrats Ravi and welcome to the team. We're really excited to work with you!

Welcome to the team @jberchuck We're very happy to have and congrats on setting up the Berchuck lab🥂

⁦@DrFadloKhuri⁩ presenting on global challenges to lung cancer therapy adoption at the 2024 DDHO at Sea Island GA ⁦@AUB_Lebanon⁩ ⁦@WinshipAtEmory⁩

🔥 session w these ⭐️s at #ASCO24 👊personal brand = what people think when they think about YOU (we all have one) 👊social media is one sphere of influence but think of your Venn diagram of spheres 👊self-promotion isn’t a dirty word for women 👊be authentic @WinshipAtEmory

Round of applause from #ASCO24 plenary session to @RamalingamMD and team for the results of LAURA trial @WinshipAtEmory

Our GU med onc team presentations on Day 3 #ASCO24 @WinshipAtEmory @jackiebrown_MD @AhmetYildirimMD @bilenma @VikramNarayan @ssjoshimd @virajmaster 9:00am-12pm Happening now - join us if here!

LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO ➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️ ➡️ 24-mo PFS: 65% vs 13% 📈 ➡️ 81% received osi at progression 💊, Good! ➡️AE discontinuation**: 13% vs 5% ⚠️ Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data courtesy: @FordePatrick’s tweet! @OncoAlert

❗️Make sure not to miss this education session and my talk on “Recognizing, Celebrating, and Supporting #IMGs in Oncology” at #ASCO24 ❗️ Today, 10-10:15 AM Room S102 @ASCO @OncoAlert @IMG_Oncologists

Abs#4510 #ASCO24 @ASCO Modified FOLFIRINOX for first line Rx of advanced urachal carcinoma. Doses, regimen and results👇Encouraging ORR~61%. Key takeaways 👇 @OncoAlert @urotoday